A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Clinical trial NCT02519348 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02519348
- Sponsor
- MedImmune LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-10-19
- Primary completion
- 2020-11-06
- Enrollment
- 433
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.